Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

TScan Therapeutics

Request full access

An experienced group of scientists, development specialists, and other leaders driving a cutting edge platform

Waltham, United StatesFounded 2018Biotech & Life Sciences

About TScan Therapeutics

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer patients. The company's primary focus is on creating therapies for hematologic malignancies, specifically targeting residual leukemia cells to prevent relapse following hematopoietic stem cell transplantation. TScan's lead candidates, TSC-100 and TSC-101, are currently in development for these purposes.

Operating in the biopharmaceutical sector, TScan serves patients with cancer, particularly those undergoing stem cell transplants. The company employs a business model centered around research and development (R&D) of innovative therapies, with revenue generation primarily through funding, grants, and potential future sales of approved therapies. TScan's market includes healthcare providers, hospitals, and specialized cancer treatment centers.

The company makes money by advancing its pipeline of TCR-T therapies through clinical trials, securing partnerships, and eventually commercializing its products upon regulatory approval.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021
Employees
152
Open positions
2
Dealroom signal
64.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Dec 2024 $30M — Undisclosed ↗
POST IPO DEBTDebt Dec 2024 $53M — Silicon Valley Bank ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

TScan Therapeutics website traffic

Latest recorded traffic for TScan Therapeutics is 9K monthly website visits, up 55.2% over the last three months. TScan Therapeutics's team declined 12.1% over the past year.

Latest monthly visits9K 3-month web change+55.2% 1-year team growth-12.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

TScan Therapeutics in the Waltham ecosystem

Live from Dealroom

The TScan Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later4 investors entered at this stage

Other known investors1 additional known investor

  • Harvard University
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about TScan Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TScan Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.